5 results about "Pramipexole" patented technology

A pramipexole xinafoate and a sustained-release pharmaceutical formulation thereof are provided. The pramipexole is prepared into its xinafoate, enabling reducing a solubility of the pramipexole salts. A suspension liquid formulation prepared from the pramipexole xinafoate has a good sustained-release effect and good stability, and is suitable for large-scale production.

Provided are a long-acting sustained-release pramipexole preparation and a method for preparing same. The long-acting sustained-release pramipexole preparation comprises pramipexole pamoate or pramipexole palmitate, and a polylactic acid-glycolic acid copolymer or polylactic acid. The drug loading capacity of the preparation is 10%-50%. The molar ratio of lactic acid to glycolic acid of the polylactic acid-glycolic acid copolymer is 85:15-95:5. The microsphere is round in shape, smooth in surface and free of pores, and can effectively reduce the early burst release of the drug and solve the problem of high burst release of existing pramipexole pamoate microspheres. Also, the present invention features an effectively prolonged sustained-release period that solves the problem of the short release period of the existing pramipexole pamoate microspheres, and a smaller blood concentration fluctuation that leads to a more stable release.

Abstract The present invention relates to a method for modulating neuropathies. The method comprises: administering to a subject a therapeutically effective amount of doxazosin, a pharmaceutically acceptable salt or an acceptable form thereof, a therapeutically effective amount of pramipexole, a pharmaceutically acceptable salt or an acceptable form thereof, and a 5 therapeutically effective amount of metoprolol, a pharmaceutically acceptable salt or an acceptable form thereof. Abstract 20 26 20 52 65 03 J ul 2 02 6 A b s t r a c t 2 0 2 6 2 0 5 2 6 5 0 3 J u l 2 0 2 6

The application belongs to the technical field of medicine synthesis, and particularly relates to a preparation method of tetrahydrozoline. The tetrahydrozoline is synthesized from trifluoromethylaniline and 2-cyanoacetic acid ethyl ester under the action of an alkaline catalyst, the method has mild conditions, simple and easy-to-operate post-treatment and purification, low energy consumption, short working hours, and is suitable for large-scale production.

The invention belongs to the field of biological medicine, and particularly relates to a novel medical application of a dopamine receptor stimulant pramipexole (PPX) as an inhibitor of the activity of sapovirus 2C RNA helicase ATPase, and the inhibitor is pramipexole. In-vitro enzymology experiments prove that the pramipexole can remarkably inhibit the ATP enzyme activity of the SaV 2C RNA helicase, and the inhibition effect of the pramipexole is quantitatively verified through a malachite green-ammonium molybdate colorimetric method. The invention further discloses that pramipexole and SaV-2C RNA helicase form stable interaction (the binding energy is-126.53 kJ / mol) through molecular docking, and the key interaction comprises four hydrogen bonds mediated by Asp47 and Glu48 residues, hydrophobic interaction between the four hydrogen bonds and Leu30, Ala31 and Trp46, and electrostatic force generated by the four hydrogen bonds and Glu48. The invention has the potential of preventing and treating sapovirus infection diseases.